Article
Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens.
Clinical pharmacology and therapeutics - 1 Jul 2023
Kehinde Oyinlade, Ramsey Laura B, Gaedigk Andrea, Oni-Orisan Akinyemi
Abstract excerpt
Over 20% of US Food and Drug Administration (FDA)-approved drugs in the United States are metabolized by the hepatic enzyme cytochrome P450 2D6 (CYP2D6). The gene encoding CYP2D6 is highly polymorphic and genetic variation has been shown to impact drug response for many commonly dispensed drugs including opioids and antidepressants. Thus, it is important to understand an individual's CYP2D6 metabolizer status to...
Topics
- Cytochrome P-450 CYP2D6
- Pharmacogenetics
- Genotype
- Antidepressive Agents
- Pharmaceutical Preparations